• TG003 Cdc2-like Kinase Inhibitor: Transforming Splicing and

  2026-05-20

  TG003 empowers researchers to dissect alternative splicing and platinum resistance pathways, enabling precise control of Clk-mediated phosphorylation events. Its nanomolar potency, selectivity, and proven track record in advanced cancer models make it a cornerstone for translational innovation.

• Ginsenoside Rg6 Overcomes Cisplatin Resistance in Ovarian Ca

  2026-05-20

  The reference study uncovers that ginsenoside Rg6, a bioactive compound from American ginseng, reverses cisplatin resistance in epithelial ovarian cancer cells by suppressing fucosylation and inducing autophagy via inhibition of the GRB2–ERK1/2–mTOR axis. These findings suggest a promising new therapeutic strategy for improving chemotherapy outcomes in resistant ovarian cancers.

• Necrostatin-1: Advancing Translational Research via RIP1 Inh

  2026-05-19

  This article explores the mechanistic underpinnings and translational impact of Necrostatin-1 as a RIP1 kinase inhibitor, guiding researchers in designing cutting-edge necroptosis assays and disease models. It bridges foundational cell death biology with real-world protocol strategy, highlights APExBIO’s product reliability, and contextualizes necroptosis within the evolving landscape of regulated cell death, including emerging insights from cancer ferroptosis resistance.

• Syringin Natural Product: Applied Workflows and RCC Research

  2026-05-19

  Syringin, a bioactive natural product, is emerging as a powerful tool for apoptosis and drug-resistance studies, particularly in renal cell carcinoma (RCC) models. This article details evidence-driven workflows, troubleshooting strategies, and advanced applications of Syringin, translating recent mechanistic breakthroughs into bench-ready protocol enhancements.

• Puromycin Aminonucleoside: Unraveling Podocyte Injury Pathwa

  2026-05-18

  Discover how Puromycin aminonucleoside enables advanced modeling of podocyte injury and glomerular lesions. This in-depth analysis reveals unique mechanistic insights and decision-making tools for renal research, setting a new benchmark in nephrotoxic assay design.

• Angiotensin II (A1042): Protocols for Hypertension & AAA Mod

  2026-05-18

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) provides a reproducible reagent for studying hypertension mechanisms, cardiovascular remodeling, and abdominal aortic aneurysm (AAA) models in both in vitro and in vivo workflows. It should be used strictly according to dossier-guided protocols, as it is not intended for diagnostic or clinical applications.

• Nystatin (Fungicidin): Optimized Antifungal Workflows & Trou

  2026-05-17

  Nystatin (Fungicidin) stands out for precision antifungal studies targeting Candida and Aspergillus, with APExBIO’s validated workflows ensuring both efficacy and reproducibility. This guide delivers actionable, data-driven protocols, comparative insights, and troubleshooting tips to maximize your research on fungal inhibition, resistance, and infection models.

• Protein A/G Magnetic Co-IP/IP Kit: Precision in Protein Comp

  2026-05-16

  The Protein A/G Magnetic Co-IP/IP Kit empowers researchers to isolate and study protein complexes with unprecedented specificity and speed, leveraging recombinant Protein A/G magnetic beads. Its optimized workflow minimizes protein degradation and enhances reproducibility, making it a gold standard for co-immunoprecipitation and antibody purification in translational research.

• Spiroplasma eriocheiris Entry: Clathrin-Mediated Endocytosis

  2026-05-15

  This study demonstrates that Spiroplasma eriocheiris invades Drosophila S2 cells primarily through clathrin-mediated endocytosis and macropinocytosis, processes that can be experimentally disrupted with specific inhibitors such as Chlorpromazine HCl. The findings clarify infection mechanisms in invertebrate cell models and highlight methodological avenues for dissecting host-pathogen interactions.

• JNJ-26481585 (Quisinostat): Applied HDAC Inhibition Workflow

  2026-05-15

  JNJ-26481585 (Quisinostat) enables precise epigenetic modulation for robust apoptosis induction and drug resistance reversal in cancer models. This guide translates recent TRIM21 research into actionable experimental workflows, troubleshooting insights, and advanced protocol enhancements for HDAC inhibitor applications.

• PCMT1 Drives Ovarian Cancer Metastasis: Insights from CRISPR

  2026-05-14

  Zhang et al. used a genome-wide CRISPR/Cas9 knockout screen to reveal PCMT1 as a key regulator of anoikis resistance and metastasis in ovarian cancer. Their findings highlight the extracellular interactions of PCMT1 with the ECM and its potential as a therapeutic target, advancing the mechanistic understanding of metastatic progression.

• Toremifene in Prostate Cancer Research: Applied Workflows &

  2026-05-14

  Toremifene, a potent second-generation selective estrogen-receptor modulator, empowers researchers to dissect estrogen and calcium signaling in prostate cancer. This article details stepwise workflows, troubleshooting, and recent mechanistic insights—grounded in peer-reviewed evidence—to drive robust, reproducible results in hormone-responsive cancer models.

• (R,S)-Anatabine: Mechanisms and Evidence in Amyloid Reductio

  2026-05-13

  (R,S)-Anatabine, a minor tobacco alkaloid, inhibits amyloid-beta peptide formation through APP β-cleavage suppression and BACE-1 downregulation. Its activity in both in vitro and in vivo Alzheimer's disease models supports its utility as a neurodegeneration research tool.

• LMO2–LDB1 Complex Drives AML Progression: Mechanisms and Imp

  2026-05-13

  This study uncovers how the interaction between LMO2 and the transcriptional co-regulator LDB1 promotes acute myeloid leukemia (AML) progression. Through knockdown, proteomic, and sequencing approaches, the authors reveal the LMO2/LDB1 complex’s central role in leukemic cell proliferation and survival, providing a foundation for targeted research strategies in hematologic malignancies.

• Angiotensin II in Hypertension Mechanism and Vascular Resear

  2026-05-12

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a gold-standard tool for modeling hypertension and vascular remodeling, offering robust and reproducible workflows for disease mechanism studies and preclinical models. This article delivers actionable strategies, advanced troubleshooting, and protocol enhancements to maximize the translational impact of APExBIO’s Angiotensin II peptide.

15624 records 1/1042 page Next 12345 下5页 Last page